Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities? - Wikidata - awgldk - TriplyDB

Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?

Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?

http://www.wikidata.org/entity/Q34726350

about

Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database.Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas.Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes.Incidence rate and patient characteristics of severe hypoglycemia in treated type 2 diabetes mellitus patients in Japan: Retrospective Diagnosis Procedure Combination database analysis.

P2860

Q35887463-6AE66C8D-42A3-4664-BD85-6DCF2F274908 Q38644587-67A04680-3515-4965-AB4C-73BD3DDCC5FC Q38682317-59F7D05F-8E51-40BD-BA00-5872CDAC1D2A Q48240188-1A127FDB-AFA5-4A68-AC75-A16F3824B348

P2860

Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?

http://www.wikidata.org/entity/Q34726350

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Higher Risk of Hypoglycemia wi ...... gent Patient Susceptibilities?

@ast

Higher Risk of Hypoglycemia wi ...... gent Patient Susceptibilities?

@en

Higher Risk of Hypoglycemia wi ...... gent Patient Susceptibilities?

@nl

type

label

Higher Risk of Hypoglycemia wi ...... gent Patient Susceptibilities?

@ast

Higher Risk of Hypoglycemia wi ...... gent Patient Susceptibilities?

@en

Higher Risk of Hypoglycemia wi ...... gent Patient Susceptibilities?

@nl

prefLabel

Higher Risk of Hypoglycemia wi ...... gent Patient Susceptibilities?

@ast

Higher Risk of Hypoglycemia wi ...... gent Patient Susceptibilities?

@en

Higher Risk of Hypoglycemia wi ...... gent Patient Susceptibilities?

@nl

P1433

Q34726350-211F7634-EF04-442C-94DE-671EFC2E1726

P1476

Q34726350-AF76FFE9-C3D8-45C1-A333-C323CABD6E0E

P2093

Q34726350-0439B22F-34AD-4E9F-9CF7-6278F1F3E04D

Q34726350-3C8EC8ED-7726-4E80-9452-6CEF2BC5AC9D

Q34726350-47AFE91E-18D1-482F-BA06-7E9EA5D2EB5C

Q34726350-5B14BD28-3471-4FB8-BFB6-3A680155B0F5

Q34726350-906EB0CE-6FF4-4BE7-BCC8-1BBE7640E57A

Q34726350-DC249638-F405-4B34-A6F6-BE40ED20255F

Q34726350-EB2A6F80-D114-4740-B3ED-D664D510EBB0

P2860

Q34726350-22ECCC4B-5857-421E-BA4F-47CD87C30EAC

Q34726350-25F1C475-C8B6-4F82-954D-D013D0C58705

Q34726350-3FFD7379-3F42-41F3-9FF1-71F4FACFE304

Q34726350-471C6420-5E2A-4DE8-A462-BE4859EC05AF

Q34726350-50A5D350-B067-46E8-B6F5-C261CF70FF8C

Q34726350-51EB2C9E-2DED-474C-8647-FA6B7ACA1E35

Q34726350-5719BDDB-918A-485E-805C-5CC167C5202B

Q34726350-6B45F20E-2B49-4437-BC3D-A6E66A4086AC

Q34726350-6CED8EFE-83EC-408B-958A-92017A25BC98

Q34726350-750EDFEA-33E6-48A6-9AC7-3928DAD586F2

P2888

Q34726350-0E735FBE-AAA8-48D0-A62C-6719A04D8916

P304

Q34726350-A432E016-FF04-4DA6-8F29-95BDDDC980B6

P31

Q34726350-8E7F21B3-BB30-4825-97F3-6F0836B9F558

P356

Q34726350-BDEFECD1-EC6F-470A-BF3B-757DF88240B8

P433

Q34726350-B173B3F0-0DA3-4F75-A84E-11BE452726A3

P478

Q34726350-7DFA2A4F-1DB6-413F-A6E8-7792FF67C6B1

P50

Q34726350-0417811D-5613-4765-B5E8-997DFCCEFB98

P577

Q34726350-5CA95305-F76C-42FB-AF5E-803F5842D4E2

P5875

Q34726350-5C72EB4E-1AC1-4CCB-A36E-809B1B9648F8

P6179

Q34726350-B855B8FE-6990-4973-8366-2FAA93D7112D

P698

Q34726350-33F6F42E-E8AF-4EF2-8673-37FD42283B51

P921

Q34726350-18C77D5B-DE97-472F-BD89-64A126C788D8

Q34726350-E4E299FE-F6DB-4EAD-AFB1-DB75E97CF616

P932

Q34726350-BDAED6A0-CE63-4C49-ACC1-4EF6FECD103B

P356

S13300-014-0082-Y

P1433

Diabetes Therapy

P1476

Higher Risk of Hypoglycemia wi ...... gent Patient Susceptibilities?

@en

P2093

Anja Schweizer

http://www.w3.org/2001/XMLSchema#string

Guenter Heimann

http://www.w3.org/2001/XMLSchema#string

James Edward Foley

http://www.w3.org/2001/XMLSchema#string

Markus Dworak

http://www.w3.org/2001/XMLSchema#string

Mouna Akacha

http://www.w3.org/2001/XMLSchema#string

Qing Shao

http://www.w3.org/2001/XMLSchema#string

Sylvie Dejager

http://www.w3.org/2001/XMLSchema#string

P2860

Oral Antidiabetic Agents

GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience.

Pathogenesis of impaired glucose tolerance and type II diabetes mellitus--current status.

Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes.

Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes.

β-cell function, incretin effect, and incretin hormones in obese youth along the span of glucose tolerance from normal to prediabetes to type 2 diabetes.

Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes.

Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal n

P2888

s13300-014-0082-y

P304

459-469

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13300-014-0082-Y

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-09-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265791513

http://www.w3.org/2001/XMLSchema#string

P6179

1045302818

http://www.w3.org/2001/XMLSchema#string

P698

25230877

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

4269641

http://www.w3.org/2001/XMLSchema#string